EARNINGS-Regeneron profit rises nearly 13% on higher demand for eczema drug Dupixent
Nov 5 - Regeneron Pharmaceuticals Inc REGN.O reported a 12.6% rise in third-quarter profit on Tuesday, boosted by higher sales of its eczema drug, Dupixent.
Net income rose to $669.6 million, or $5.86 per share, in the quarter ended Sept. 30, from $594.7 million, or $5.17 per share, a year earlier.
Total revenue rose 23.1% to $2.05 billion.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))